Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00408629
First received: December 5, 2006
Last updated: April 28, 2011
Last verified: April 2011
  Purpose

This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of the human anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab (ADA) in patients with moderately to severely active ulcerative colitis (UC).


Condition Intervention Phase
Ulcerative Colitis
Biological: adalimumab
Biological: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis

Resource links provided by NLM:


Further study details as provided by Abbott:

Primary Outcome Measures:
  • Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 [ Time Frame: Week 8 ] [ Designated as safety issue: No ]

    Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

    Stool Frequency Subscore (SFS), Rectal Bleeding Subscore (RBS), Endoscopy Subscore, and Physician's Global Assessment Subscore (PGA), each of which ranges from 0 (normal) to 3 (severe disease).


  • Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]

    Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

    SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).



Secondary Outcome Measures:
  • Proportion of Participants Who Achieved Sustained Clinical Remission Per Mayo Score at Both Week 8 and Week 52 [ Time Frame: Week 8, Week 52 ] [ Designated as safety issue: No ]

    Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

    SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).


  • Proportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 8 [ Time Frame: Week 8 ] [ Designated as safety issue: No ]

    Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in rectal bleeding subscore (RBS) of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

    SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).


  • Proportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]

    Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in RBS of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

    SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).


  • Proportion of Participants Who Achieved Sustained Clinical Response Per Mayo Score at Both Week 8 and Week 52 [ Time Frame: Week 8, Week 52 ] [ Designated as safety issue: No ]

    Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in RBS of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

    SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).


  • Proportion of Participants Who Achieved Mucosal Healing at Week 8 [ Time Frame: Week 8 ] [ Designated as safety issue: No ]

    Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows:

    0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration).


  • Proportion of Participants Who Achieved Mucosal Healing at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]

    Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows:

    0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration).


  • Proportion of Participants Who Achieved Sustained Mucosal Healing at Both Week 8 and Week 52 [ Time Frame: Week 8, Week 52 ] [ Designated as safety issue: No ]

    Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows:

    0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration).


  • Proportion of Participants Who Discontinued Corticosteroid Use Before Week 52 and Achieved Clinical Remission Per Mayo Score at Week 52 [ Time Frame: Baseline to Week 52 ] [ Designated as safety issue: No ]

    Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

    SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).


  • Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8 [ Time Frame: Week 8 ] [ Designated as safety issue: No ]

    The PGA includes the 3 other subscores (SFS, RBS, and Endoscopy), the participant's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the participant's performance status. Possible scores range from 0-3 as follows:

    0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3).


  • Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8 [ Time Frame: Week 8 ] [ Designated as safety issue: No ]

    SFS ranges from 0-3 as follows:

    0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal. The participant served as his/her own control.


  • Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8 [ Time Frame: Week 8 ] [ Designated as safety issue: No ]

    RBS ranges from 0-3 as follows:

    0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed


  • Proportion of Participants Who Discontinued Corticosteroid Use for At Least 90 Days and Achieved Clinical Remission Per Mayo Score at Week 52 [ Time Frame: Baseline to Week 52 ] [ Designated as safety issue: No ]

    Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

    SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).


  • Proportion of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission Per Mayo Score (Sustained) at Both Weeks 32 and 52 [ Time Frame: Week 32, Week 52 ] [ Designated as safety issue: No ]

    Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

    SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease).


  • Proportion of Inflammatory Bowel Disease Questionnaire Responders at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
    Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) was defined as at least a 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to questions within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

  • Proportion of Inflammatory Bowel Disease Questionnaire Responders at Week 8 [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) was defined as at least a 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to questions within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).


Enrollment: 518
Study Start Date: November 2006
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: adalimumab group Biological: adalimumab
Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.
Other Names:
  • ABT-D2E7
  • adalimumab
  • Humira
Experimental: placebo group Biological: placebo
Matching Placebo for prefilled syringe, 40 mg,
Other Name: placebo

Detailed Description:

This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of adalimumab (ADA) in patients with moderately to severely active ulcerative colitis (UC).

The duration of the study was up to 65 weeks, including a Screening Period of up to 3 weeks, a double-blind (DB) placebo-controlled treatment period of up to 52 weeks, and a 70 day follow-up phone call for participants who prematurely discontinued or who did not enroll in the extension study NCT# 00573794 (M10-223).

Adult participants with moderate to severe UC (Mayo score of 6 to 12 points with endoscopy subscore of 2 to 3 points), confirmed by colonoscopy with biopsy or flexible sigmoidoscopy with biopsy, were to be enrolled at approximately 120 sites worldwide. Planned enrollment was 500 participants.

Participants were to be stratified by prior exposure to infliximab and/or other anti-TNF agents, and randomized in a 1:1 ratio to receive ADA or placebo by subcutaneous injection. Participants assigned to the ADA treatment arm were to receive an induction dose of 160 mg at Week 0 and 80 mg at Week 2, and 40 mg every other week (eow) starting at Week 4. Participants assigned to the placebo treatment arm were to receive matching placebo during the same period of time. At or after Week 10, participants who met the criteria for inadequate response could be switched to open-label (OL) ADA 40 mg eow beginning at Week 12. Inadequate response was defined as:

  • Partial Mayo score greater than or equal to Baseline score on 2 consecutive visits at least 14 days apart (for participants with a partial Mayo score of 4 to 7 at Baseline).
  • Partial Mayo score greater than or equal to 7 on 2 consecutive visits at least 14 days apart (for participants with a partial Mayo score of 8 or 9 at Baseline).

Participants who demonstrated inadequate response at 2 consecutive visits at least 14 days apart while on OL administration ADA 40 mg eow were permitted to dose escalate to ADA 40 mg weekly (ew). Participants with persistent inadequate response while on ADA 40 mg ew may have been discontinued from the study at the Investigator's discretion. Upon completion of the study, participants had the option to enroll into the OL extension Study M10-223 in which they could receive ADA treatment.

Efficacy and safety measurements were performed throughout the study. A follow-up phone call was made 70 days after the last dose of study drug to obtain information on any ongoing or new adverse events (AEs) for all participants who terminated early or who did not enroll in the OL extension study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participants >=18 years of age and in good health (Investigator discretion) with a recent stable medical history
  2. Diagnosis of UC for greater than 90 days prior to Baseline
  3. Diagnosis of active UC confirmed by colonoscopy with biopsy or flexible sigmoidoscopy with biopsy during the Screening Period, with exclusion of infection
  4. Active UC with a Mayo score of 6 to 12 points and endoscopy subscore of 2 to 3 points, despite concurrent treatment with at least 1 of the following (oral corticosteroids or immunosuppressants or both as defined below):

    • Stable oral corticosteroid dose (prednisone >= 20 mg/day or equivalent) for at least 14 days prior to Baseline or maintenance, corticosteroid dose (prednisone < 20 mg/day or equivalent) for at least 40 days prior to Baseline

    and/or

    • At least a 90 day course of azathioprine (AZA) or 6-mercaptopurine (6-MP) prior to Baseline, with a dose of AZA >= 1.5 mg/kg/day or 6-MP >= 1 mg/kg/day (rounded to the nearest available tablet formulation), or a dose that is the highest tolerated by the participant (e.g., due to leukopenia, elevated liver enzymes, nausea) during that time. Participant must be on a stable dose for at least 28 days prior to Baseline.

    Concurrent therapy was not required for participants who were previously treated with corticosteroids or immunosuppressants (AZA or 6-MP) during the past 5 years and in the judgment of the Investigator have failed to respond to, or could not tolerate, their treatment.

  5. Participants may have been included if they had previously used an anti-tumor necrosis factor (TNF) agent (except ADA) and discontinued its use due to a loss of response or intolerance to the agent.
  6. Had to be able to self-administer or had caregiver who could reliably administer subcutaneous (SC) injections.
  7. Had to be able and willing to give written informed consent and to comply with the requirements of the study protocol.
  8. Female had to be either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or of childbearing potential and practicing an approved method of birth control throughout the study and for 150 days after the last dose of study drug. Examples of approved methods of birth control included the following:

    • Condoms, sponge, foams, jellies, diaphragm, or intrauterine device
    • Oral, parenteral, intravaginal contraceptives for 90 days prior to study drug administration
    • A vasectomized partner The results of the serum pregnancy test performed at the Screening Visit and urine pregnancy test performed at the Baseline Visit must have been negative.
  9. Judged to be in generally good health as determined by the Investigator

Exclusion Criteria:

  1. History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for UC, or planned bowel surgery.
  2. Received previous treatment with ADA or previous participation in an ADA clinical study.
  3. Received cyclosporine, tacrolimus, or mycophenolate mofetil within 30 days of Baseline.
  4. Received intravenous (IV) corticosteroids within 14 days of Screening or during the Screening Period.
  5. Received therapeutic enema or suppository, other than required for endoscopy, within 14 days of the Screening endoscopy and during the remainder of the Screening Period.
  6. Current diagnosis of fulminant colitis and/or toxic megacolon.
  7. Disease limited to the rectum (ulcerative proctitis).
  8. Current diagnosis of indeterminate colitis.
  9. Current diagnosis and/or history of Crohns disease (CD).
  10. Currently receiving total parenteral nutrition.
  11. Used aminosalicylates for < 90 days before Baseline or not on a stable dose for at least 28 days before Baseline or discontinued use within 28 days of Baseline.
  12. Positive Clostridium difficile stool assay.
  13. Previously used infliximab or any anti-TNF agent within 56 days of Baseline.
  14. Previously used infliximab or any anti-TNF agent without clinical response at any time ("primary non-responder") unless subject experienced a treatment-limiting reaction.
  15. Infections requiring treatment with IV antibiotics, antivirals, or antifungals within 30 days of Baseline or oral antibiotics, antivirals, or antifungals within 14 days of Baseline.
  16. History of malignancy other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix. If the Screening colonoscopy/flexible sigmoidoscopy showed evidence of dysplasia or a malignancy, subject was not to be enrolled in the study.
  17. History of listeria, histoplasmosis, chronic or active hepatitis B infection, human immunodeficiency virus (HIV), immunodeficiency syndrome, central nervous system demyelinating disease, or untreated tuberculosis (TB).
  18. Female subject who was pregnant or breast-feeding or considering becoming pregnant during the study (there should be at least 150 days between the last dose of study drug and either conception or initiation of breast-feeding in women of childbearing potential).
  19. Poorly controlled medical condition(s), such as uncontrolled diabetes, unstable ischemic heart disease, moderate to severe congestive heart failure (CHF), recent cerebrovascular accident, and any other condition, which in the opinion of the investigator, put the subject at risk by participation in the protocol.
  20. Received any investigational agent within 30 days or 5 half lives prior to Baseline (whichever was longer).
  21. History of clinically significant drug or alcohol abuse during the past year.
  22. Known hypersensitivity to the excipients of ADA as stated in the label.
  23. Any prior exposure to Tysabri® (natalizumab), or Orencia® (abatacept) or any other biological therapy [other than Kineret® (anakinra) and anti-TNF agents].
  24. Currently taking both budesonide and prednisone (or equivalent) simultaneously.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00408629

  Hide Study Locations
Locations
United States, California
Site Ref # / Investigator 5394
Anaheim, California, United States, 92801
United States, Colorado
Site Ref # / Investigator 3753
Wheat Ridge, Colorado, United States, 80033
United States, Connecticut
Site Ref # / Investigator 3754
Hamden, Connecticut, United States, 06518
United States, Florida
Site Ref # / Investigator 12903
Gainesville, Florida, United States, 32607
Site Ref # / Investigator 3747
Hollywood, Florida, United States, 33021
Site Ref # / Investigator 5106
Jacksonville, Florida, United States, 32256
Site Ref # / Investigator 11601
Naples, Florida, United States, 34102
Site Ref # / Investigator 6846
Sarasota, Florida, United States, 34239
Site Ref # / Investigator 3742
Winter Park, Florida, United States, 32789
Site Ref # / Investigator 3760
Zephyrhills, Florida, United States, 33542
United States, Georgia
Site Ref # / Investigator 3739
Atlanta, Georgia, United States, 30342
Site Ref # / Investigator 7658
Macon, Georgia, United States, 31201
United States, Illinois
Site Ref # / Investigator 5397
Moline, Illinois, United States, 61265
United States, Kansas
Site Ref # / Investigator 7453
Topeka, Kansas, United States, 66606
United States, Maryland
Site Ref # / Investigator 3759
Annapolis, Maryland, United States, 21401
Site Ref # / Investigator 3762
Annapolis, Maryland, United States, 21401
Site Ref # / Investigator 3738
Lutherville, Maryland, United States, 21093
United States, Michigan
Site Ref # / Investigator 7472
Troy, Michigan, United States, 48098
United States, Minnesota
Site Ref # / Investigator 3744
Rochester, Minnesota, United States, 55905
United States, Missouri
Site Ref # / Investigator 6088
St. Louis, Missouri, United States, 63128
United States, New York
Site Ref # / Investigator 3756
Great Neck, New York, United States, 11021
United States, North Carolina
Site Ref # / Investigator 3752
Charlotte, North Carolina, United States, 28207
Site Ref # / Investigator 3758
Jacksonville, North Carolina, United States, 28546
United States, Ohio
Site Ref # / Investigator 3745
Cincinnati, Ohio, United States, 45219
United States, Oklahoma
Site Ref # / Investigator 7709
Oklahoma City, Oklahoma, United States, 73104
Site Ref # / Investigator 3740
Tulsa, Oklahoma, United States, 74104
United States, Pennsylvania
Site Ref # / Investigator 3765
Sayre, Pennsylvania, United States, 18840
United States, South Carolina
Site Ref # / Investigator 3741
Columbia, South Carolina, United States, 29204
United States, Tennessee
Site Ref # / Investigator 3737
Germantown, Tennessee, United States, 38138
Site Ref # / Investigator 3743
Nashville, Tennessee, United States, 37212-1610
Site Ref # / Investigator 6077
Nashville, Tennessee, United States, 37203
Site Ref # / Investigator 5107
Nashville, Tennessee, United States, 37205
United States, Utah
Site Ref # / Investigator 5398
Ogden, Utah, United States, 84405
United States, Washington
Site Ref # / Investigator 3750
Spokane, Washington, United States, 99204
Site Ref # / Investigator 8064
Spokane, Washington, United States, 99202
United States, Wisconsin
Site Ref # / Investigator 3761
West Bend, Wisconsin, United States, 53095
Argentina
Site Ref # / Investigator 6853
Buenos Aires, Argentina, C1181ACH
Australia, Australian Capital Territory
Site Ref # / Investigator 13722
Garran, Australian Capital Territory, Australia, 2605
Australia, New South Wales
Site Ref # / Investigator 16141
Bankstown, New South Wales, Australia, NSW 2200
Australia, Queensland
Site Ref # / Investigator 13723
Herston, Queensland, Australia, 4029
Australia, South Australia
Site Ref # / Investigator 10706
Bedford Park, South Australia, Australia, SA 5042
Australia, Victoria
Site Ref # / Investigator 14882
Box Hill, Victoria, Australia, 3128
Site Ref # / Investigator 9002
Malvern, Victoria, Australia, 3144
Australia, Western Australia
Site Ref # / Investigator 10704
Fremantle, Western Australia, Australia, 6160
Austria
Site Ref # / Investigator 9802
Vienna, Austria, 1090
Belgium
Site Ref # / Investigator 5256
Bonheiden, Belgium, 2820
Site Ref # / Investigator 6225
Brussels, Belgium, 1200
Site Ref # / Investigator 5253
Brussels, Belgium, 1070
Site Ref # / Investigator 6079
Ghent, Belgium, 9000
Site Ref # / Investigator 6078
Leuven, Belgium, 3000
Canada, British Columbia
Site Ref # / Investigator 10423
Kelowna, British Columbia, Canada, B1Y 1Z9
Site Ref # / Investigator 3766
Victoria, British Columbia, Canada, V8T 5G4
Canada, Ontario
Site Ref # / Investigator 3769
Hamilton, Ontario, Canada, L8N 3Z5
Site Ref # / Investigator 13556
Sudbury, Ontario, Canada, P3E 2N8
Site Ref # / Investigator 3736
Toronto, Ontario, Canada, M5G 1X5
Canada, Quebec
Site Ref # / Investigator 3764
Montreal, Quebec, Canada, H3G 1A4
Site Ref # / Investigator 3771
Montreal, Quebec, Canada, H3A 1A1
Site Ref # / Investigator 3768
Montreal, Quebec, Canada, H3T 1E2
Site Ref # / Investigator 3770
Quebec City, Quebec, Canada, G1S 4L8
Czech Republic
Site Ref # / Investigator 7021
Ceske Budejovice, Czech Republic, 370 87
Site Ref # / Investigator 6307
Hradec Kravlove 12, Czech Republic, 500 12
Site Ref # / Investigator 6606
Olomouc, Czech Republic, 775 20
Site Ref # / Investigator 7481
Prague 4, Czech Republic, 140 21
Site Ref # / Investigator 7479
Prague 5, Czech Republic, 15006
Denmark
Site Ref # / Investigator 6483
Hvidovre, Denmark, DK-2650
Site Ref # / Investigator 7477
Odense C, Denmark, 5000
France
Site Ref # / Investigator 6231
Clichy, France, 92110
Site Ref # / Investigator 7476
Lille Cedex, France, 59037
Site Ref # / Investigator 7475
Pessac Cedex, France, 33600
Site Ref # / Investigator 7474
Toulouse, France, 31059
Germany
Site Ref # / Investigator 9069
Hamburg, Germany, 22559
Site Ref # / Investigator 15321
Hamburg, Germany, 20148
Site Ref # / Investigator 14642
Magdeburg, Germany, 39120
Site Ref # / Investigator 9067
Minden, Germany, 32423
Site Ref # / Investigator 14761
Muenster, Germany, 48159
Site Ref # / Investigator 9801
Munich, Germany, 81377
Site Ref # / Investigator 14661
Munich, Germany, 80639
Site Ref # / Investigator 5247
Regensburg, Germany, 93053
Hungary
Site Ref # / Investigator 7485
Budapest, Hungary, H-1076
Site Ref # / Investigator 5025
Budapest, Hungary, H-1135
Site Ref # / Investigator 10625
Debrecen, Hungary, 4032
Site Ref # / Investigator 14104
Gyula, Hungary, 5700
Site Ref # / Investigator 4987
Miskoic, Hungary, H-3051
Site Ref # / Investigator 5036
Miskolc, Hungary, H-3526
Israel
Site Ref # / Investigator 12744
Kfar Saba, Israel, 44281
Site Ref # / Investigator 10623
Petah Tikva, Israel, 49100
Site Ref # / Investigator 15361
Tel Aviv, Israel, 64239
New Zealand
Site Ref # / Investigator 13181
Auckland, New Zealand, 1148
Site Ref # / Investigator 13301
Auckland, New Zealand, 0620
Site Ref # / Investigator 13148
Christchurch, New Zealand, 8011
Site Ref # / Investigator 13482
Hamilton, New Zealand
Norway
Site Ref # / Investigator 9561
Gjovik, Norway, 2819
Site Ref # / Investigator 6297
Oslo, Norway, 0514
Site Ref # / Investigator 5197
Oslo, Norway, 0027
Site Ref # / Investigator 5194
Tromso, Norway, 9038
Site Ref # / Investigator 5193
Trondheim, Norway, 7006
Poland
Site Ref # / Investigator 5242
Lodz, Poland, 90-153
Site Ref # / Investigator 5266
Warsaw, Poland, 02 781
Site Ref # / Investigator 5265
Warsaw, Poland, 02-507
Site Ref # / Investigator 15263
Wroclaw, Poland, 54-144
Portugal
Site Ref # / Investigator 5264
Faro, Portugal, 8000-386
Site Ref # / Investigator 5263
Lisbon, Portugal, 1769-001
Site Ref # / Investigator 7473
Lisbon, Portugal, 1150-314
Spain
Site Ref # / Investigator 5211
Barcelona, Spain, 08036
Site Ref # / Investigator 5212
Madrid, Spain, 28040
Switzerland
Site Ref # / Investigator 10221
Basel, Switzerland, 4031
Site Ref # / Investigator 10222
Bern, Switzerland, 3010
Site Ref # / Investigator 9162
Zurich, Switzerland, 8091
Sponsors and Collaborators
Abbott
Investigators
Study Director: Roopal B Thakkar, M.D. Abbott
  More Information

No publications provided by Abbott

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Roopal B Thakker, M.D./Project Director, Abbott
ClinicalTrials.gov Identifier: NCT00408629     History of Changes
Other Study ID Numbers: M06-827, 2006-002782-40
Study First Received: December 5, 2006
Results First Received: March 3, 2011
Last Updated: April 28, 2011
Health Authority: Canada: Health Canada
United States: Food and Drug Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Australia: Department of Health and Ageing Therapeutic Goods Administration
Austria : Federal Ministry for Labour, Health, and Social Affairs
Belgium: Federal Agency for Medicinal Products and Health Products
Czech Republic: State Institute for Drug Control
Denmark: Danish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Paul-Ehrlich-Institut
Hungary: National Institute of Pharmacy
Israel: Ministry of Health
New Zealand: Medsafe
Norway: Norwegian Medicines Agency
Poland: Ministry of Health
Portugal: National Pharmacy and Medicines Institute
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Switzerland: Swissmedic

Keywords provided by Abbott:
Ulcerative Colitis
Adalimumab
TNF Antagonist
Mayo Score

Additional relevant MeSH terms:
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Inflammatory Bowel Diseases
Pathologic Processes
Adalimumab
Antirheumatic Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on April 17, 2014